These are RCC patients with clear cell histology, treated using the PME-CD40L DC product. At present, 6 of the 12 patients that have been restaged using RECIST criteria have less tumor burden that when they enrolled in the study (15 weeks earlier).

Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial. Most patients having received the vaccine already demonstrated broad responses to numerous peptides prior vaccination. Significantly enhanced responses to several peptides and occurrence of new responses was seen in 6 patients, 5 of which were vaccinated with E/L-S+ DC. These data provide evidence for a superior immunopotency of E/L-selectin expressing DC.

An HIV infected individuals stable under HAART study has been initiated. These patients are being vaccinated with cytokine cocktail matured DCs electroporated with mRNA encoding Tat, Rev and Nef. The cDNA’s encoding these early expressed HIV antigens have been human codon optimized and modified with lysosomal targeting sequences. So far, 17 patients have been included in the study.

Aiming at finding possible reasons for the discrepancies between our findings and published data could be the amount of ONTAK used in patients, we filed an amendment to the clinical trial allowing the inclusion of additional 4 patients. These patients will receive higher doses (12microg/kg 3x and 18microg/kg 1x) before vaccination. Taking into account direct effects of ONTAK on DC, patients will be vaccinated some days after last ONTAK treatment (as soon as blood DC have recovered to 50% of pre ONTAK amount). Third stage of DERMA-ER-DC 05 clinical trial.

Four patients are enrolled in a clinical trial for vaccination with DC loaded with apoptotic leukemic cells. A strong type I T cell response has been induced. Preliminary data also indicate reduction of circulating tumor cells. No adverse effects have been observed.

These patients are taking part in a clinical study. They are patients that are successfully treated with highly active anti-retroviral therapy (HAART) with no measurable viral load AND have a cryopreserved infectious plasma sample that was drawn immediately prior to initiation of HAART. They are administered 4 monthly doses of the Arcelis product.

These 70 patients were evaluated in the DERMA-ER-DC 04 clinical trial of DC-based therapy of melanoma patients (multipeptide loaded cytokine matured moDC +/- CD40L activation). The analysis for the first time showed a clinical correlation of induced immune responses as measured in the blood with outcome, as there have been so far statistically significantly less events in stage III patients showing good CTL reponses (IFN-y Elispot) to multiple class I and II peptides compared to low responders of the stage III cohort. Additional in vitro maturation of DC by CD...

77 patients have been enrolled in two Phase III trials from 2 institutions testing dosing or duration of IM administration (EORTC 62005 and BFR14 trials).

These patients received multipeptide loaded cytokine matured moDC + prior Treg elimination by 3x ONTAK treatment [5µg/kg]; first phase of DERMA-ER-DC 05 trial.

These patients with Previously Treated B-cell Chronic Lymphocytic Leukemia are taking part in a clinical study and receive multiple injections of CLL-DCV01.

These patients receive a DC vaccine composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).

The B-CLL patients were vaccinated with autologous, apoptotic, leukemic cells (Apo-DC). The first cohort of patients received the vaccine without additional adjuvants, while the next cohort of 5 patients who receive the vaccine with GM-CSF as an adjuvant. Clinical trial on vaccination of B-CLL patients with autologous, apoptotic, leukemic cells (Apo-DC), progressed further in 2007. Cohort 1 with the vaccine alone and cohort 2 (5 patients) combining the vaccine together with GM-CSF as an adjuvant has finished accrual and all patients in these two cohorts have ...

Three patients were enrolled in a clinical trial of a DC vaccine administered into irradiated tumours in RCC. However only this one patient received the vaccine due to cancer progression in the other two patients. The DC were labelled with 111In. The following patients will receive DC labelled with Endorem and the vaccine will be imaged with MRI. The patient treated is in complete remission 6 months after treatment.

Three groups of end stage cervical cancer patients (in total N=35) were subcutaneously vaccinated with HPV16 E6 combined with or separated from HPV16 E7 overlapping long peptides in Montanide ISA-51 adjuvant, 4 times at three week intervals. Group 1 received 300 microgram per peptide at a single site, group 2 received 100 microgram per peptide of the E6 peptides in one limb, and 300 microgram per peptide of the E7 peptides in a second limb. Group 3 received separate injections of E6 and E7 peptides, each at a dose of 50 micrograms per peptide. The primary endpo...

This patient has received 6 vaccines with peptide only in a randomized trial to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4). The patient received a sequence of six immunizations every two weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4 in Cycle 1. In Cycle 2, the patient received a sequence of three immunizations every six weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restric...

Blood samples and tumour biopsies will be taken from these newly diagnosed glioblastoma patients in order to carry out a preclinical study in which circulating tumour-specific CD8+ T-cells will be detected in their blood. In order to obtain the blood samples and tumour biopsies, a file has been submitted to the Ethics Committee of the Erasme Hospital and has been recently approved.

The patients are immunized with autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24.

These patients undergo leukapheresis and later intradermal administration of the produced vaccine (V administrations of autologous dendritic cells generated from adherent peripheral blood monocytes and subject to quality controls - with eventual additional ones depending on clinical outcome).

An HLA-A2 positive healthy donor underwent leukapheresis with the aim to generate monocyte derived DC under GMP conditions.

The patients are immunized with autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24.